Regeneron
REGN
Performance
About Regeneron
Regeneron is a biopharmaceutical company that harmonizes biology and technology to develop life-changing medicines. Its focus spans biologics and genetic medicines across oncology/hematology, inflammatory diseases, neuroscience, respiratory and other serious conditions, with operations and clinical development rooted in the United States and global collaborations. The company emphasizes research and development, clinical trials, and a commitment to responsible practices and patient access. Headquartered in the U.S., Regeneron positions itself at the intersection of science and medicine to bring therapies to patients worldwide.
Recent News
Regeneron Reports P-III (NIMBLE) Trial Data on Cemdisiran for Generalized Myasthenia Gravis (gMG)
Asian Marco Initial Thoughts: US/Iran Stand-Off the Main Focus; Oil Price Rising. Warsh Nomination for Fed Chair to Be Voted on Wednesday, Central Banks Rate Decisions in Focus This Week.
Gene Therapy Gives Deaf Toddlers Hearing After One Injection
FDA Approves Otarmeni, First Gene Therapy for Genetic Hearing Loss
Tuneable Peptide Biotech Parabilis Files IPO
Outlook Therapeutics Narrows Q2 Loss, Awaits FDA Decision on LYTENAVA in May 2026
Sanofi Reports the CHMP Positive Opinion for Cenrifki (Tolebrutinib) to Treat Non-Relapsing SPMS
The Rise of Trispecific Antibodies: Biopharma’s Next Big Bet After Bispecifics
Regeneron Inks a ~$2.3B Deal with Parabilis Medicines to Advance Antibody-Helicon Conjugates Across Multiple Therapeutic Areas
New AAD Leaders Aim to Fix ‘Broken’ Access to Care, Serve Next Generation of Dermatologists
Parabilis Reveals IPO Plans the Day After Regeneron Deal as Listings Heat Up
Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies
Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie
Regulatory Actions for April 24, 2026
Lunsotogene Parvec Becomes First FDA-Approved Gene Therapy for OTOF-Related Hearing Loss
Regeneron Basks in First Gene Therapy Approval as Dupixent, Eylea Carry Robust Q1 Earnings
Regeneron Reaches $125M Parabilis Deal for Hard-to-Catch Drug Targets
Trump Administration Secures Regeneron Deal to Slash Medicaid Drug Prices, Cuts Praluent to $225
#JPM26: Regeneron, Lilly, Summit on Rivals Crowding Into Same Targets
What Does 17 Pharma MFN Deals Are Underneath the Press Releases: The Real Primary Source Stack, the GLP1 Numbers, TrumpRX Plumbing, and Where the New Adjudication Layer Gets Monetized
STAT+: Pharmalittle: We’re Reading About U.S. Biotech’s China Problem, a Regeneron Flop, and Much More
What the Smart Money Just Bought in Healthcare and Life Sciences VC Over the Last Sixty Days
BrightInsight Secures $13M Funding Round
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline
FDA Approves Otarmeni, First Gene Therapy to Restore Hearing in OTOF‑Related Deafness
Regeneron Will Offer Rare Disease Therapy Free As Part Of TrumpRx Deal
Fed Rate Cut Tailwind, Lilly’s Triple Agonist Delivers Big, Vaccine Policy Turmoil — This Week in Biotech #81
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
FDA Approves First-Ever Gene Therapy For Deafness, Opening Door To New Era
Hiring Outlook: February Brings First YOY Job Increase Since 2022
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
Gene Therapy Reduces Geographic Atrophy Lesion Growth
Høeg Fired in Latest FDA Shakeup; 20 People Die After Taking Amgen Drug
Early Intervention an Unmet Need in Diabetic Macular Edema
Sanofi and Regeneron Win FDA Approvals as AbbVie Faces Rejection; Lilly Buys Kelonia
STAT+: Trump Celebrates Closing First Round of Drug Pricing Deals, Promises More Ahead
5 Key April FDA Approvals Signal Momentum Across Rare, Chronic Diseases
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
2025 Novel Large Molecule FDA Drug Approvals
Intellia Raises $180 M, Files BLA After First In‑Vivo CRISPR Phase 3 Success
The BioPharm Brief: ADC Expansion, Early Breast Cancer, Biosimilar Momentum
Regeneron, Parabilis Set Out to Create New Drug Class in Deal Worth up to $2.3B
Sanofi's Bispecific Lunsekimig Has Mixed Readouts in Phase 2
An Opinionated Take on NEJM Highlights for Q1 of 2026
FDA Approves the First PROTAC in History, a $1B siRNA Wave Hits Cardiometabolic Disease, and Cytokinetics Cracks Non-Obstructive HCM – This Week in Biotech #99
AbbVie Turbocharges Its US Investment Promise to $100bn
The Next Wave of Biotech Growth — a Perspective
DDW 2026: Key Readouts From the Conference
AbbVie, Gubra Post Obesity Data; Regeneron Obesity Drug Succeeds in China